CSIMarket
 


Audentes Therapeutics Inc   (BOLD)
Other Ticker:  
 

Cumulative Audentes Therapeutics Inc 's Leverage Ratio for Trailing Twelve Months Period

BOLD's Leverage Ratio for Trailing Twelve Months Period and Total Liabilities, Equity growth


Select the Comparisons : Select the Ratio:

BOLD Leverage Ratio for Trailing Twelve Months Period

(Sep 30 2019)
III. Quarter
(Jun 30 2019)
II. Quarter
(Mar 31 2019)
I. Quarter
(Dec 31 2018)
IV. Quarter
(Sep 30 2018)
III. Quarter
Y / Y Equity Growth 23.48 % 23.09 % 14.06 % 182.73 % 77.13 %
Y / Y Total Liabilities Growth 100.79 % 119.89 % 144.14 % 35.07 % 9.2 %
Leverage Ratio for Trailing Twelve Months Period 0.12 0.1 0.09 0.07 0.08
Total Ranking # 223 # 176 # 148 # 165 # 168
Seq. Equity Growth -8.64 % 4.4 % -9.21 % 42.57 % -8.92 %
Seq. Total Liabilities Growth -0.93 % 9.44 % 69.15 % 9.49 % 8.49 %


Leverage Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2019
On the trailing twelve months basis Despite debt repayement of -0.93% in III. Quarter, Leverage Ratio for Trailing Twelve Months Period improved to 0.12, below Audentes Therapeutics Inc 's average Leverage Ratio for Trailing Twelve Months Period.
Leverage Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies in Biotechnology & Pharmaceuticals industry 18 other companies have achieved lower Leverage Ratio for Trailing Twelve Months Period than Audentes Therapeutics Inc . While total ranking remained unchanged compare to previous quarter at no. .

What is Leverage Ratio?
Who are BOLD's Customers?
Leverage Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 19
Sector # 113
S&P 500 # 286


Leverage Ratio for Trailing Twelve Months Period Statistics
High Average Low
0.19 0.12 0.07
(Mar 31 2017)   (Dec 31 2018)




Companies with similar average Leverage Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2019, within Biotechnology & Pharmaceuticals Industry Leverage Ratio for Trailing Twelve Months Period
Eloxx Pharmaceuticals Inc   0.31 
Gritstone Bio Inc   0.29 
Fate Therapeutics Inc   0.29 
Palisade Bio Inc   0.29 
Denali Therapeutics Inc   0.27 
Avalon Globocare Corp   0.27 
Cellular Biomedicine Group Inc   0.26 
Crispr Therapeutics Ag  0.26 
Replimune Group Inc   0.26 
Repligen Corp  0.25 
Anavex Life Sciences Corp   0.24 
Erytech Pharma S a   0.24 
Kaleido Biosciences Inc   0.24 
Ladrx Corporation  0.23 
Bluebird Bio Inc   0.22 
Immunitybio inc   0.21 
Cellectis S a   0.20 
Rubius Therapeutics Inc   0.20 
Twist Bioscience Corporation  0.20 
Seagen Inc   0.18 
Adaptimmune Therapeutics Plc  0.18 
Enzon Pharmaceuticals inc   0.18 
Polarityte Inc   0.17 
Aptose Biosciences Inc   0.15 
Solid Biosciences Inc   0.15 
Aceragen Inc   0.15 
Protara Therapeutics Inc   0.15 
Organovo Holdings Inc   0.15 
Logicbio Therapeutics Inc   0.13 
Fresh Tracks Therapeutics Inc   0.13 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com